文献速递冠心病肺血管病与心包/心肌炎

利伐沙班联合阿司匹林在亚洲与非亚洲慢性冠心病或外周动脉疾病患者中的比较:COMPASS试验

Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.
PubMed 文献 · Eur Heart J · 2022-01-01

COMPASS试验的事后分析比较了亚洲与非亚洲慢性冠心病和/或外周动脉疾病患者中利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次与阿司匹林单药的疗效与安全性。亚洲患者颅内出血和轻微出血发生率更高,但联合治疗降低主要不良心血管事件的效果在两组间一致,颅内出血在亚洲患者中可能更高。

要点

  • 亚洲患者颅内出血和轻微出血发生率高于非亚洲患者。
  • 联合治疗降低MACE的效应在亚洲与非亚洲患者中一致。
  • 亚洲患者联合治疗的颅内出血风险可能更高,需权衡获益与风险。

核心结论

  • 亚洲慢性冠心病和/或外周动脉疾病患者颅内出血和轻微出血发生率高于非亚洲患者。
  • 利伐沙班联合阿司匹林对比阿司匹林单药对MACE、改良ISTH大出血和净临床结局的影响在亚洲与非亚洲患者中相似,但亚洲患者颅内出血可能更高。

研究设计与样本

  • COMPASS试验的事后分析,比较利伐沙班2.5 mg每日两次联合阿司匹林100 mg每日一次与阿司匹林100 mg每日一次。

主要发现

  • 亚洲与非亚洲患者MACE发生率分别为4.85%与4.83%(P=0.30)。
  • 亚洲与非亚洲患者改良ISTH大出血发生率分别为2.72%与2.58%(P=0.22)。
  • 亚洲与非亚洲患者颅内出血发生率分别为0.63%与0.29%(P=0.01),轻微出血分别为13.61%与6.49%(P<0.001)。
  • 联合治疗对比阿司匹林单药降低MACE的HR在亚洲患者为0.64(95%CI 0.45-0.90),非亚洲患者为0.78(95%CI 0.67-0.90),异质性P=0.29。
  • 联合治疗增加改良ISTH大出血的HR在亚洲患者为2.24(95%CI 1.40-3.58),非亚洲患者为1.60(95%CI 1.30-1.97),异质性P=0.20。

临床怎么用

  • 亚洲慢性冠心病和/或外周动脉疾病患者使用利伐沙班联合阿司匹林时,需关注颅内出血风险。
  • 联合治疗降低MACE的获益在亚洲与非亚洲患者中一致,但需个体化评估出血风险。

局限性

  • 种族为自我认定。
  • 为COMPASS试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: It is unknown whether Asian and non-Asian patients with atherosclerotic vascular disease derive similar benefits from long-term antithrombotic therapy. METHODS AND RESULTS: In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d. were compared with those of aspirin 100 mg o.d. in Asian vs. non-Asian patients (race was self-identified). Asians (n = 4269) vs. non-Asians (n = 23 126) had similar rates of major adverse cardiovascular events (MACEs) (4.85% vs. 4.83%, P = 0.30) and modified International Society on Thrombosis and Haemostasis (ISTH) major bleeding (2.72% vs. 2.58%, P = 0.22), but higher rates of intracranial haemorrhage (ICH) (0.63% vs. 0.29%, P = 0.01) and minor bleeding (13.61% vs. 6.49%, P < 0.001). In Asians vs. non-Asians, the combination of rivaroxaban and aspirin compared with aspirin alone produced consistent reductions in MACE [Asians: hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.45-0.90; non-Asians: HR: 0.78, 95% CI: 0.67-0.90; P(heterogeneity) = 0.29], increases in modified ISTH major bleeding (Asians: HR 2.24, 95% CI: 1.40-3.58; non-Asians: HR: 1.60, 95% CI: 1.30-1.97; P = 0.20), and net clinical outcome (Asians: HR: 0.77, 95% CI: 0.56-1.05; non-Asians: HR: 0.81, 95% CI: 0.70-0.93, P = 0.78), but borderline higher rates of ICH (Asians: HR: 3.50, 95% CI: 0.98-12.56; non-Asians: HR: 0.81, 95% CI: 0.43, 1.53; P = 0.04). CONCLUSION: Asian compared with non-Asian patients with chronic CAD and/or PAD have higher rates of ICH and minor bleeding. The combination of rivaroxaban and aspirin vs. aspirin alone produces similar effects for MACE, modified ISTH major bleeding, and net clinical outcome but may be associated with higher rates of ICH in Asian patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hori M, Zhu J, Liang Y, et al. Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. Eur Heart J. 2022. PMID: 35751528. doi:10.1093/eurheartj/ehac309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。